Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy.
Khan S, Lutzky J, Shoushtari AN, Jeter J, Marr B, Olencki TE, Cebulla CM, Abdel-Rahman M, Harbour JW, Sender N, Nesson A, Singh-Kandah S, Hernandez S, King J, Katari MS, Dimapanat L, Izard S, Ambrosini G, Surriga O, Rai AJ, Chiuzan C, Schwartz GK, Carvajal RD.
Khan S, et al. Among authors: rai aj.
Front Oncol. 2022 Aug 29;12:976837. doi: 10.3389/fonc.2022.976837. eCollection 2022.
Front Oncol. 2022.
PMID: 36106113
Free PMC article.